HLS Therapeutics Inc Total Liabilities
HLS Therapeutics Inc total liabilities. Based on the latest financial reports, HLS Therapeutics Inc (HLS) has total liabilities worth CA$75.72 Million CAD (≈ $54.78 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check HLS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of HLS Therapeutics Inc (1996–2025)
Total liabilities of HLS Therapeutics Inc from 1996 to 2025. This chart illustrates how HLS Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
HLS Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of HLS Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Farcent Enterprise Co Ltd
TW:1730
|
Taiwan | NT$584.97 Million |
|
Interojo Inc
KQ:119610
|
Korea | ₩98.92 Billion |
|
Tanami Gold NL
AU:TAM
|
Australia | AU$5.12 Million |
|
Alcidion Group Ltd
AU:ALC
|
Australia | AU$27.82 Million |
|
Thai Plaspac Public Company Limited
BK:TPAC
|
Thailand | ฿4.87 Billion |
|
Hektar Real Estate Investment Trust
KLSE:5121
|
Malaysia | RM707.97 Million |
|
Voss Veksel og Landmandsbank ASA
OL:VVL
|
Norway | Nkr5.92 Billion |
|
Wieson Technologies Co Ltd
TWO:6272
|
Taiwan | NT$2.52 Billion |
Liability Composition Analysis (1996–2025)
This chart breaks down HLS Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see HLS Therapeutics Inc (HLS) total assets.
Liquidity & Leverage Metrics
HLS Therapeutics Inc Total Liabilities Ratios Explained
HLS Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HLS Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HLS Therapeutics Inc (1996–2025)
The table below shows the annual total liabilities of HLS Therapeutics Inc from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$75.72 Million ≈ $54.78 Million |
-14.50% |
| 2024-12-31 | CA$88.56 Million ≈ $64.07 Million |
-20.47% |
| 2023-12-31 | CA$111.36 Million ≈ $80.56 Million |
-4.27% |
| 2022-12-31 | CA$116.33 Million ≈ $84.15 Million |
+1.01% |
| 2021-12-31 | CA$115.17 Million ≈ $83.31 Million |
-14.47% |
| 2020-12-31 | CA$134.66 Million ≈ $97.41 Million |
-4.82% |
| 2019-12-31 | CA$141.47 Million ≈ $102.34 Million |
-4.37% |
| 2018-12-31 | CA$147.94 Million ≈ $107.01 Million |
-27.58% |
| 2017-12-31 | CA$204.26 Million ≈ $147.76 Million |
+36901.53% |
| 2016-12-31 | CA$552.04K ≈ $399.34K |
-3.52% |
| 2015-12-31 | CA$572.17K ≈ $413.90K |
-95.74% |
| 2014-12-31 | CA$13.42 Million ≈ $9.71 Million |
-6.10% |
| 2013-12-31 | CA$14.29 Million ≈ $10.34 Million |
+64.46% |
| 2012-12-31 | CA$8.69 Million ≈ $6.28 Million |
-35.40% |
| 2011-12-31 | CA$13.45 Million ≈ $9.73 Million |
+10.51% |
| 2010-12-31 | CA$12.17 Million ≈ $8.80 Million |
-30.62% |
| 2009-12-31 | CA$17.54 Million ≈ $12.69 Million |
+0.07% |
| 2008-12-31 | CA$17.53 Million ≈ $12.68 Million |
-37.18% |
| 2007-12-31 | CA$27.90 Million ≈ $20.18 Million |
+50.64% |
| 2006-12-31 | CA$18.52 Million ≈ $13.40 Million |
+30.65% |
| 2005-12-31 | CA$14.18 Million ≈ $10.25 Million |
+22.65% |
| 2004-12-31 | CA$11.56 Million ≈ $8.36 Million |
-22.00% |
| 2003-12-31 | CA$14.82 Million ≈ $10.72 Million |
+255.47% |
| 2002-12-31 | CA$4.17 Million ≈ $3.02 Million |
-29.57% |
| 2001-12-31 | CA$5.92 Million ≈ $4.28 Million |
-54.82% |
| 2000-12-31 | CA$13.10 Million ≈ $9.48 Million |
-43.87% |
| 1999-12-31 | CA$23.34 Million ≈ $16.88 Million |
+31.05% |
| 1998-12-31 | CA$17.81 Million ≈ $12.88 Million |
-25.92% |
| 1997-12-31 | CA$24.04 Million ≈ $17.39 Million |
+138.23% |
| 1996-12-31 | CA$10.09 Million ≈ $7.30 Million |
-- |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more